TYRA trades 118.1% below Wall Street's consensus target of $50.67.
Last 12 months price action with 12-month analyst target path
The base valuation assumes TYRA achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Tyra Biosciences, Inc. (TYRA) has a Wall Street consensus price target of $50.67, based on estimates from 7 covering analysts. With the stock currently trading at $23.23, this represents a potential upside of +118.1%. The company has a market capitalization of $1.39B.
Analyst price targets range from a low of $42.00 to a high of $56.00, representing a 28% spread in expectations. The median target of $54.00 differs from the mean, suggesting potential outlier estimates.
The current analyst consensus rating is Buy, with 7 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, TYRA trades at a trailing P/E of -11.6x. Analysts expect EPS to grow -18.6% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 KROSKeros Therapeutics, Inc. | $372M | $11.63 | $20.33 | +74.8% | Buy | — | 17 |
 NUVLNuvalent, Inc. | $9.1B | $123.96 | $127.32 | +2.7% | Hold | — | 19 |
 PRAXPraxis Precision Medicines, Inc. | $7.9B | $282.12 | $603.83 | +114.0% | Buy | — | 18 |
 MRUSMerus N.V. | $6.8B | $90.00 | $88.69 | -1.5% | Hold | — | 22 |
 ERASErasca, Inc. | $4.8B | $13.95 | $22.50 | +61.3% | Buy | — | 11 |
 RGENRepligen Corporation | $10.4B | $184.53 | $162.43 | -12.0% | Buy | 89.5x | 24 |
 ICLRICON Public Limited Company | $12.5B | $163.90 | $170.64 | +4.1% | Buy | 15.5x | 30 |
 CRLCharles River Laboratories International, Inc. | $13.4B | $277.33 | $282.36 | +1.8% | Buy | 24.5x | 37 |
 MEDPMedpace Holdings, Inc. | $17.2B | $617.15 | $606.38 | -1.7% | Hold | 35.1x | 19 |
 ARVNArvinas, Inc. | $505M | $7.83 | $14.17 | +81.0% | Buy | — | 26 |
Quick answers to the most common questions about buying TYRA stock.
The consensus Wall Street price target for TYRA is $50.67, representing 118.1% upside from the current price of $23.23. With 7 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
TYRA has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 7 Buy/Strong Buy ratings. The consensus 12-month price target of $50.67 implies 118.1% upside from current levels.
TYRA's current price is $23.23 with a consensus target of $50.67 (118.1% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $56 for TYRA, while the most conservative target is $42. The consensus of $50.67 represents the median expectation. These targets typically reflect 12-month expectations.
TYRA is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 7 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month TYRA stock forecast based on 7 Wall Street analysts shows a consensus price target of $50.67, with estimates ranging from $42 (bear case) to $56 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on TYRA, with a "Buy" consensus rating and $50.67 price target (118.1% upside). 7 of 7 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
TYRA analyst price targets range from $42 to $56, a 28% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $50.67 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.